Grab your favorite coffee. This is where you’ll find all the substance you require, and more.
From covariates to confounding factors: the danger of having too many covariates
Clinical trials typically evaluate efficacy of experimental therapies in heterogeneous patient populations, as patient characteristics vary significantly. These patient characteristics might be prognostic factors that ultimately induce…
Regulatory Guidelines for the Use of Baseline Covariates to Increase Clinical Trial Study Power
Clinical trials data analyses can employ baseline covariates to control for factors that may impact measurement of outcomes – particularly to describe individual patient characteristics that may…
Does the placebo response need to be considered in clinical trials for COVID-19 vaccines and treatments?
The search for drugs to treat and prevent SARS-CoV-2 infection is ongoing, with more than 1200 drugs in the pipeline and more 3,200 clinical trials planned or…
Frequently asked questions about COV-IQ
This webinar aimed to explain the impact of COVID-19 crisis on patient behavior in ongoing clinical trials, introduce the application of COV-IQ technology and describe how it…
Pandemic Stress Will Affect Clinical Trial Response: What Can Industry Do?
As one might expect, the life changes are a source of stress, and the data supports this assertion. In fact, a recent analysis by Express Scripts also…
The placebo response in drug development. Part 2: Osteoarthritis
Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more…
Understand patient differences in your next clinical trial
Increase your trial’s success rates and bring new therapies to patients faster.
Tell us about your clinical trial below, and our team will be in touch.
"*" indicates required fields